BioSpace News Archive

Biotin’s upsurge in popularity has led to a parallel rise in incidents of this health supplement interfering with critical medical tests.

Global Healthcare Exchange (GHX) today announced it has acquired Chicago-based Lumere, a leading provider of evidence-based data and analytics solutions that enable healthcare organizations to build clinically integrated supply chains and optimize medication formulary management.

Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation and a leader in diagnostic medical imaging systems, along with NZ Technologies of Vancouver Canada and developers of TIPSOTM technology, today announced that they have signed a one-year renewable agreement that allows Shimadzu to market and sell the innovative TIPSO AirPad® in the US healthcare market.

Neptune Wellness Solutions Inc. (“Neptune” or the “Company”) (Nasdaq: NEPT) (TSX: NEPT), a health and wellness company focused on extraction, purification and formulation of cannabinoids, would like to provide an update on its non-core investments.

The updated guideline for estrogen and progesterone receptor (ER/PgR) testing in breast cancer, published jointly today by the College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO), reaffirms much of the original guidance and has more specific recommendations for handling and reporting cases with low ER expression.

Geneoscopy, Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal (GI) health, today announced that its preventive screening test for colorectal cancer and precancerous adenomas earned FDA Breakthrough Device Designation

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, provided today an overview of select expected fourth quarter 2019 financial results, initial 2020 financial guidance and upcoming corporate milestones.

Biogen Inc. (Nasdaq: BIIB) today announced an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and neurological diseases

Cytokinetics, Inc. (Nasdaq: CYTK) today announced its Vision 2025 and provided guidance for corporate milestones expected to occur in 2020.

Waters Corporation announced that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics.